Protagenic Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.4M | $-3.6M | $-5.5M | $-5.0M | $-3.6M | $-4.5M | $-2.5M | $-1.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $49.2K | — | $50.3K | $28.2K | $30 | — | $286 | $339 |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $418.6K | — | $923.1K | $666.8K | $864.7K | $1.5M | $1.7M | $797.8K |
| Net Cash from Operating Activities | $-2.8M | $-1.8M | $-4.2M | $-3.7M | $-2.0M | $-2.8M | $-1.3M | $-488.0K |
| Investing Activities | ||||||||
| Capital Expenditures | $3.3K | — | — | $149.8K | $1.8K | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $629.9K | — | $2.8M | $4.8M | $1.6M | $-9.9M | — | $250.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.9M | $1.8M | $2.0M | — | — | $12.6M | $1.2M | $670.0K |
| Net Change in Cash | — | — | $550.6K | $1.1M | $-326.0K | $-129.9K | $-127.5K | $436.1K |
| Free Cash Flow | $-2.8M | — | — | $-3.9M | $-2.0M | — | — | — |